Nadine Wong Recommends Genentech; and Highlights OSI

 Pharmaceutical, Xoma, Tanox, Novartis, AstraZeneca, and ImClone 
Business Editors 
CHICAGO--(BUSINESS WIRE)--March 19, 2003--Biotechnology companies
often find themselves twisting in the wind until their next
blockbuster drug is approved, making it difficult for investors. But
Expert Biotech Investor Nadine Wong highlights one company that brings
profit potential to the forefront. Learn about Genentech (NYSE:DNA),
as well as OSI Pharmaceutical (NASDAQ:OSIP), Xoma (NASDAQ:XOMA), Tanox
(NASDAQ:TNOX), Novartis (NYSE:NVS), AstraZeneca (NYSE:AZN) and ImClone
(NASDAQ:IMCL). Click here for the full story exclusively on 
Here are the highlights from the Featured Expert column: 
Genentech's (NYSE:DNA) share price has fallen as investors
speculate over its cancer drug, Avastin. (Avastin is a monoclonal
antibody that inhibits angiogenesis by binding to vascular endothelial
growth factor (VEGF). Investors need to focus on the Phase III
clinical data expected to be released in mid-2003, which should
clarify matters. The data will include information for 900 patients
and a smaller 200 patient supportive Phase III trial studying Avastin
in colorectal cancer. 
Avastin has been widely seen as having the greatest profit
potential of any in Genentech's pipeline, because it's the only one of
the four big products that Genentech wholly owns. Revenues generated
from sales of upcoming biologicals Tarceva, Raptiva and Xolair will be
shared with OSI Pharmaceutical (NASDAQ:OSIP), Xoma (NASDAQ:XOMA) and
Tanox (NASDAQ:TNOX) and Novartis (NYSE:NVS), respectively. 
Investors should also watch closely for the release of clinical
trial data with Tarceva in non-small cell lung cancer (NSCLC) expected
in mid-2003. Tarceva is an epidermal growth factor receptor (EGFR)
inhibitor. Based on the mixed clinical results seen in similar EGFR
inhibitors such as AstraZeneca's (NYSE:AZN) Iressa and ImClone's
(NASDAQ:IMCL) Erbitux, it looks like Wall Street is discounting the
potential of Tarceva for this cancer. However, the Oncology Drugs
Advisory Committee to the Food and Drug Administration, recently voted
11 to 3 that results in third line advanced NSCLC were "reasonably
likely to predict clinical benefit". This means that Tarceva, Iressa
and Erbitux still have a chance. 
Nadine Wong views 2003 as a turning point for Genentech with the
odds in favor that the company will introduce one new product to the
market. Over the long haul, Genentech has a deep pipeline with 20
projects in development as well as five in Phase III and that the
company will likely have little difficulty in achieving its 5-by-5
goal of 25% average annual earnings growth in 1998-05. 
It's hard to find specific biotech news like this anywhere else!
Don't miss your chance to make money in this space though Nadine
Wong's detailed commentary and stock recommendations by clicking: 
About Zacks Featured Experts 
To be a successful investor you need professional advice. Experts
who know what they're talking about and can help you achieve your
financial goals in good markets...and especially in bad ones will help
you improve your portfolio. That is why Zacks Investment Research has
assembled the best investment experts in the business to offer their
powerful advisory newsletters to you on all the major investment
topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. 
Recommendations from Featured Experts Highlighted in FREE
Investment Newsletter 
The best way to tap into the powerful advice from these experts is
through our free weekly e-mail newsletter, "Profit from the Pros".
Each week we highlight several Featured Experts in this free e-mail
newsletter. Get your free subscription to "Profit from the Pros" at: 
About Zacks is a property of Zacks Investment Research, Inc., which
was formed in 1981 to compile, analyze, and distribute investment
research to both institutional and individual investors. The guiding
principle behind our work is the belief that investment experts, such
as brokerage analysts and investment newsletter writers, have superior
knowledge about how to invest successfully. Our goal is to unlock
their profitable insights for our customers. And there is no better
way to enjoy this investment success, than with a FREE subscription to
"Profit from the Pros" weekly e-mail newsletter. For your free
newsletter, visit 
Zacks Investment Research is under common control with affiliated
entities (including a broker-dealer and an investment adviser), which
may engage in transactions involving the foregoing securities for the
clients of such affiliates. 
Disclaimer: Past performance does not guarantee future results.
Investors should always research companies and securities before
making any investments. Nothing herein should be construed as an offer
or solicitation to buy or sell any security.
Press spacebar to pause and continue. Press esc to stop.